PAC-14028乳膏——一种新型局部外用非甾体选择性TRPV1拮抗剂治疗轻中度特应性皮炎患者的疗效与安全性:一项IIb期随机试验
这项为期8周的IIb期随机双盲多中心赋形剂对照研究纳入194例轻中度特应性皮炎患者,比较PAC-14028乳膏0.1%、0.3%、1.0%与赋形剂每日两次外用的疗效与安全性。第8周IGA成功率为赋形剂14.58%、0.1%组42.55%(P=0.0025)、0.3%组38.30%(P=0.0087)、1.0%组57.45%(P<0.001)。SCORAD指数、EASI 75/90、睡眠障碍评分和瘙痒视觉模拟量表呈改善趋势,未报告显著安全性问题。
要点
- 第8周IGA成功率为赋形剂14.58% vs PAC-14028 1.0%组57.45%(P<0.001 vs 赋形剂)。
- 0.1%组IGA成功率42.55%(P=0.0025 vs 赋形剂),0.3%组38.30%(P=0.0087 vs 赋形剂)。
- SCORAD指数、EASI 75/90、睡眠障碍评分和瘙痒视觉模拟量表呈改善趋势,未报告显著安全性问题。
核心结论
- PAC-14028乳膏可能为轻中度特应性皮炎患者的一种有效且安全的治疗方式。
研究设计与样本
- 为期8周的IIb期随机双盲多中心赋形剂对照研究,纳入194例轻中度特应性皮炎患者。
- 患者随机接受PAC-14028乳膏0.1%、0.3%、1.0%或赋形剂乳膏每日两次外用。
主要发现
- 第8周IGA成功率为赋形剂14.58% vs PAC-14028 0.1%组42.55%(P=0.0025 vs 赋形剂)。
- 第8周IGA成功率为赋形剂14.58% vs PAC-14028 0.3%组38.30%(P=0.0087 vs 赋形剂)。
- 第8周IGA成功率为赋形剂14.58% vs PAC-14028 1.0%组57.45%(P<0.001 vs 赋形剂)。
- 赋形剂与治疗组间IGA成功率在改善两级方面发现统计学显著差异。
- SCORAD指数、EASI 75/90、睡眠障碍评分和瘙痒视觉模拟量表呈改善趋势,未报告显著安全性问题。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Transient receptor potential vanilloid subfamily, member 1 (TRPV1) may play an important role in pruritus and inflammation induction in atopic dermatitis (AD). The treatment effect of TRPV1 antagonist via topical application in patients with AD remains unknown. OBJECTIVES: To assess the clinical efficacy and safety of PAC-14028, a TRPV1 antagonist, via topical application in patients with AD. METHODS: In this 8-week, phase IIb, randomized, double-blind, multicentre, vehicle-controlled study, patients with mild-to-moderate AD were randomized to receive PAC-14028 cream 0·1%, 0·3%, 1·0% or vehicle cream twice daily. The primary efficacy end point was the Investigator's Global Assessment (IGA) success rate defined as the percentage of patients with an IGA score of 0 or 1 at week 8. The secondary efficacy end points included the severity Scoring of Atopic Dermatitis (SCORAD) index and Eczema Area and Severity Index (EASI) 75/90. RESULTS: A total of 194 patients were enrolled. IGA success rates at week 8 were 14·58% for vehicle cream, 42·55% for PAC-14028 cream 0·1% (P = 0·0025 vs. vehicle), 38·30% for PAC-14028 cream 0·3% (P = 0·0087 vs. vehicle) and 57·45% for PAC-14028 cream 1·0% (P < 0·001 vs. vehicle). In particular, statistically significant differences were found between the vehicle and treatment groups in the IGA success rates with two-grade improvement. The SCORAD index, EASI 75/90, sleep disturbance score and pruritus visual analogue scale showed a trend towards improvement. No significant safety issues were reported. CONCLUSIONS: PAC-14028 cream may be an effective and safe treatment modality for the treatment of patients with mild-to-moderate AD.
引用
- Lee YW, Won CH, Jung K, et al. Efficacy and safety of PAC-14028 cream - a novel, topical, nonsteroidal, selective TRPV1 antagonist in patients with mild-to-moderate atopic dermatitis: a phase IIb randomized trial. Br J Dermatol. 2019. PMID: 30623408. doi:10.1111/bjd.17455
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。